Grace Therapeutics, Inc. (GRCE)

In the past six months, the FDA accepted the New Drug Application (NDA) for GTx-104 for formal review, setting a PDUFA target date of April 23, 2026. Data from the Phase 3 STRIVE-ON safety trial for GTx-104 was presented at the Society of Vascular and Interventional Neurology Annual Meeting. Grace Therapeutics announced its Third Quarter 2026 Financial Results and participated in the TD Cowen 46th Annual Health Care Conference. The company announced plans to present data on GTx-104 at upcoming medical conferences, and an abstract highlighting the STRIVE-ON Phase 3 trial results was accepted for presentation at AAN 2026. The FDA issued a Complete Response Letter (CRL) for the GTx-104 NDA, citing issues in the Chemistry, Manufacturing, and Controls (CMC) and non-clinical sections of the application, leading to a significant drop in the stock price. Analysts from Craig-Hallum and TD Cowen lowered their price targets for Grace Therapeutics stock following the FDA's decision.

The demand for Grace Therapeutics' specialized pharmaceutical products is typically driven by medical need and disease prevalence rather than seasonal factors. No specific information regarding demand seasonality for Grace Therapeutics' products or services was found.

Grace Therapeutics, Inc. is a biopharmaceutical company focused on developing drug candidates for rare and orphan diseases, utilizing novel technologies to enhance existing drugs. The company's primary product candidates, all with Orphan Drug Designation from the FDA, include GTx-104 for aneurysmal subarachnoid hemorrhage, GTx-102 for Ataxia-telangiectasia, and GTx-101 for Postherpetic Neuralgia. Grace Therapeutics was incorporated in 2002, is headquartered in Princeton, New Jersey, and is listed on NASDAQ.

Grace Therapeutics, Inc. develops and commercializes pharmaceutical products for rare and orphan diseases in Canada. Its lead clinical assets have been granted Orphan Drug Designation by the FDA, providing seven years of marketing exclusivity post-launch in the United States. The company's intellectual property portfolio spans the world, and its corporate office is located in Princeton, New Jersey, United States.

Grace Therapeutics' brand reputation has been significantly impacted by the regulatory process for GTx-104. The acceptance of the NDA and positive Phase 3 trial results likely contributed positively, but the Complete Response Letter from the FDA had a substantial negative effect, causing the stock to plunge. Despite the stock drop, retail sentiment showed optimism, but the overall impact of an FDA rejection is generally negative for a biopharma company's reputation.

Grace Therapeutics, Inc. is owned by a mix of institutional, insider, and retail investors. Institutional shareholders hold approximately 27.97% of the stock, insiders hold about 45.52%, and retail investors hold around 26.52%. Major institutional owners include Nantahala Capital Management, LLC, ADAR1 Capital Management, LLC, Bank Of America Corp /de/, Vanguard Group Inc, Cerity Partners LLC, Renaissance Technologies Llc, Citadel Advisors Llc, XTX Topco Ltd, Morgan Stanley, Gsa Capital Partners Llp, and Aigh Capital Management LLC. The largest individual shareholder is Grace 2018 Irrevocable Trust Rajitha, owning 4.69 million shares, representing 30.31% of the company. Other notable individual owners include George Kottayil and William A. Haseltine.